Careteq Limited
ACN 612 267 857

Level 10, 99 Queen St
Melbourne 3000
info@careteq.com.au
Phone: 1300 110 366
International: +613 8866 5594

30 October 2026

CARETEQ'S Q1 FY27 ACTIVITIES REPORT AND APPENDIX 4C

HMR Referrals platform enhancements and staged AI enablement

Careteq Limited (ASX: CTQ) ("Careteq" or "the Company"), a clinical healthtech company delivering innovative and AI-enabled healthcare solutions, is pleased to provide the following quarterly update and commentary on its Appendix 4C for the quarter ended 30 September 2026.

Highlights

- Continued development of the HMR Referrals platform for coordinating Home Medicines Reviews (HMRs), with enhanced workflow tools for GP practices and pharmacists.
- Staged AI enablement targeting document extraction, interview preparation and report-drafting assistance, with professional review and clinical responsibility retained.
- GP clinic activation and pharmacist engagement remain central priorities, supported by improved referral visibility, practice administration and pharmacist caseload tools.
- Launch of AI-enabled marketplace platform (https://hmrreferrals.com.au/)
- Cash balance of $2.71 million at quarter end, with no drawn loan or convertible note facilities.

HMR Referrals — platform development and workflow improvements

During the quarter, the Company continued development of its HMR Referrals platform, enhancing the workflow tools used to coordinate referral intake, pharmacist allocation, appointment scheduling, report preparation and follow-up management. Alongside these workflow improvements, the Company is introducing optional AI assistance for defined documentation tasks, as outlined below.

Priorities remain improving GP clinic activation, pharmacist recruitment and engagement, staged AI enablement focused on process improvements, and strategic collaborations with complementary industry partners.

The focus is on developing HMR Referrals as a more comprehensive AI-enabled platform for coordinating Home Medicines Reviews ("HMRs").

The platform enhancement programme brings together more of the administrative work surrounding an HMR into one environment. The development encompasses referral intake and allocation, appointment scheduling, case management, report preparation and follow-up coordination.

For pharmacists, the enhanced workflow includes referral offers based on nominated travel areas, availability-based appointment scheduling, patient booking links, structured case files and report preparation. Calendar export, task reminders and caseload views are designed to support day-to-day administration, while follow-up diaries and pre-filled follow-up reviews support continuity of care.

Careteq Limited
ACN 612 267 857

Level 10, 99 Queen St
Melbourne 3000
info@careteq.com.au
Phone: 1300 110 366
International: +613 8866 5594

For general practices and GPs, the development includes referral-status dashboards, alerts for unsent or expiring referrals, visibility of appointment milestones and report-delivery preferences. Practice administration tools support staff access roles, pharmacist preferences and reporting across multiple practices.

These enhancements are intended to reduce repeated manual entry, improve visibility of outstanding work and simplify participation in the HMR Referrals network. They support the Company's established priorities of activating GP clinics, engaging accredited pharmacists and improving the platform's capacity to coordinate HMR delivery.

Staged AI platform enablement

The HMR Referrals development program incorporates optional AI assistance for defined tasks within the medication-review workflow.

These capabilities include reviewing referral documents and proposing information for referral forms; extracting recorded clinical details into editable report fields; preparing draft patient-interview questions; and assisting pharmacists to structure and clarify their own report notes. A separate general clinical-reference panel is also included in the development programme.

The approach is designed to retain professional oversight at each stage. AI-generated information is presented for checking against source material, and pharmacists retain responsibility for clinical judgement and the submitted report.

Pharmacists can choose whether to use AI assistance, and forms can be completed manually. Referral matching, appointment scheduling, report delivery and follow-up tracking are workflow automation functions, distinct from the AI-assisted features.

The Company's objective is to apply AI to specific administrative and documentation tasks to support usability and scalability. The development programme remains aligned with Careteq's previously disclosed strategy of progressively introducing AI capabilities focused on process improvement.

Quarterly expenditure

During the quarter, the Company's principal operating cash expenditure comprised $130,000 in staff costs, $373,000 in administration and corporate costs and $3,000 in advertising and marketing costs. Included within the Company's expenditure during the quarter was $44,900 attributable to the HMR Referrals initiatives detailed below.

This quarter's operating cash expenditure included $160,000 of expenditures associated with the finalisation of the EHS sale; $40,000 associated with the last fundraising and the $20,000 attributable to the AI capability enhancement to the HMR Referrals platform which if adjusted for brings the cash outflow from operations in line with our on-going expected quarterly expenditures.

Use of funds – HMR Referrals

As set out in the Company's ASX announcement dated 23 July 2026, the Company committed to providing quarterly progress updates regarding the application of the $500,000 allocated to the development and commercialisation of HMR Referrals. The Company's expenditure against this allocation to 30 September 2026 is set out below:

Careteq Limited
ACN 612 267 857

Level 10, 99 Queen St
Melbourne 3000
info@careteq.com.au
Phone: 1300 110 366
International: +613 8866 5594

Focus Area	Estimate	Q1-FY27 Costs	Previous Periods	Balance
GP Clinic Activation	185,000	17,650	12,500	154,850
Pharmacist Recruitment	140,000	7,500	12,600	119,900
AI Capability	140,000	19,750	7,500	112,750
Contingency	35,000	0	0	35,000
Total	500,000	44,900	32,600	422,500

The Company's strategy is to position HMR Referrals as a focused, scalable and progressively AI-enabled platform in the healthcare sector while maintaining disciplined overhead management and preserving balance sheet flexibility.

ASX Listing Rule 4.7C.3

In accordance with ASX Listing Rule 4.7C.3, payments to related parties and their associates totalling $50k outlined in Item 6 of the Company's Appendix 4C relate to director fees, salaries, and superannuation.

ATO position update

Formal objection process remains ongoing; the Board will keep shareholders and the market informed as appropriate.

Outlook

Careteq's commercial focus remains the development and roll-out of the HMR Referrals platform, GP clinic activation, pharmacist recruitment and engagement, and strategic collaborations that can broaden participation on the platform.

The assessment of complementary acquisition opportunities also forms part of the Company's previously disclosed strategy, and the Directors continue to review such opportunities and assess their strategic fit and commercial viability.

This ASX announcement has been authorised by the Board of Careteq Limited (ASX: CTQ)

For further information, please contact:

Careteq Limited (ASX: CTQ)
Mark Simari
Executive Chairman
E: info@careteq.com.au

About Careteq Limited (ASX: CTQ)

Careteq Limited (ASX: CTQ) is an Australian healthtech company delivering innovative and AI-enabled clinical healthcare solutions. The Company is dedicated to improving healthcare outcomes through its wholly owned marketplace platform, HMR Referrals, which streamlines the process of completing Home Medicines Reviews (HMRs). To learn more, please visit: www.careteq.com.au/

Careteq Limited
ACN 612 267 857

Level 10, 99 Queen St
Melbourne 3000
info@careteq.com.au
Phone: 1300 110 366
International: +613 8866 5594

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Careteq's beliefs, assumptions, and expectations and on information currently available to Careteq. All statements that address operating performance, events or developments that Careteq or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Careteq or the market it operates in.

Careteq believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Careteq does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Careteq or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information

Follow us on LinkedIn

To learn more about Careteq please click here: https://www.careteq.com.au/investors-centre/

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Careteq Limited	
ABN	**Quarter ended ("current quarter")**
83 612 267 857	30 September 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	41	41
1.2	Payments for		
	(a) research and development	–	–
	(b) product manufacturing and operating costs	–	–
	(c) advertising and marketing	(3)	(3)
	(d) leased assets	–	–
	(e) staff costs	(130)	(130)
	(f) administration and corporate costs	(373)	(373)
1.3	Dividends received	–	–
1.4	Interest received	8	8
1.5	Interest and other costs of finance paid	(8)	(8)
1.6	Income taxes paid	–	–
1.7	Government grants and tax incentives	–	–
1.8	Other (provide details if material)	–	–
1.9	**Net cash from / (used in) operating activities**	**(465)**	**(465)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	–	–
	(b) businesses	–	–
	(c) property, plant and equipment	(2)	(2)
	(d) investments	–	–
	(e) intellectual property	–	–
	(f) other non-current assets	–	–

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	–	–
	(b) businesses	–	–
	(c) property, plant and equipment	–	–
	(d) investments	–	–
	(e) intellectual property	–	–
	(f) other non-current assets	–	–
2.3	Cash flows from loans to other entities	–	–
2.4	Dividends received (see note 3)	–	–
2.5	Other (provide details if material)	–	–
2.6	**Net cash from / (used in) investing activities**	**(2)**	**(2)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	–	–
3.2	Proceeds from issue of convertible debt securities	–	–
3.3	Proceeds from exercise of options	–	–
3.4	Transaction costs related to issues of equity securities or convertible debt securities	–	–
3.5	Proceeds from borrowings	–	–
3.6	Repayment of borrowings	–	–
3.7	Transaction costs related to loans and borrowings	–	–
3.8	Dividends paid (Note 3)	–	–
3.9	Other (provide details if material)	–	–
3.10	**Net cash from / (used in) financing activities**	–	–

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	3,177	3,177
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(465)	(465)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2)	(2)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	–	–
4.5	Effect of movement in exchange rates on cash held	–	–
4.6	**Cash and cash equivalents at end of period**	**2,710**	**2,710**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	2,710	2,710
5.2	Call deposits	–	–
5.3	Bank overdrafts	–	–
5.4	Other (provide details)	–	–
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**2,710**	**2,710**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	50
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	–	–
7.2	Credit standby arrangements	–	–
7.3	Other (Convertible Note)	–	–
7.4	**Total financing facilities**	–	–

7.5	**Unused financing facilities available at quarter end**	0

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(465)
8.2	Cash and cash equivalents at quarter end (item 4.6)	2,710
8.3	Unused finance facilities available at quarter end (item 7.5)	–
8.4	Total available funding (item 8.2 + item 8.3)	2,710
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	5.8

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: .....30th October 2026.....

Authorised by: .....By the Board of Directors of Careteq Limited.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends paid may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g. Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.